U Wisconsin launches PET lung cancer trial
The University of Wisconsin Carbone Cancer Center in Madison has enrolled the first patient in a Phase 1-2 PET imaging trial of I-124-CLR1404 (LIGHT, Novelos Therapeutics), a cancer-targeted PET imaging agent, in patients with advanced non-small cell lung cancer (NSCLC).
Anne M. Traynor, MD, of the medical oncology department at the University of Wisconsin Carbone Cancer Center, is the trial's principal investigator.
LIGHT is a small molecule imaging agent that may have potential for selective detection of tumors and metastases in various cancers, according to the Madison, Wis.-based Novelos. LIGHT is comprised of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle), labeled with the short-lived radioisotope, iodine-124, a new PET imaging isotope.
Investigator-sponsored Phase 1-2 trials of LIGHT as a PET imaging agent are ongoing. The trials include brain metastases, lung cancer and starting in the second quarter of 2012, other solid tumors. These human trials, if successful, would accelerate clinical development of HOT, chemically identical small-molecule cancer-targeted molecular radiotherapeutic, by predicting efficacy and enabling calculation of efficacious doses of HOT for Phase 2 trials, the company said.
Anne M. Traynor, MD, of the medical oncology department at the University of Wisconsin Carbone Cancer Center, is the trial's principal investigator.
LIGHT is a small molecule imaging agent that may have potential for selective detection of tumors and metastases in various cancers, according to the Madison, Wis.-based Novelos. LIGHT is comprised of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle), labeled with the short-lived radioisotope, iodine-124, a new PET imaging isotope.
Investigator-sponsored Phase 1-2 trials of LIGHT as a PET imaging agent are ongoing. The trials include brain metastases, lung cancer and starting in the second quarter of 2012, other solid tumors. These human trials, if successful, would accelerate clinical development of HOT, chemically identical small-molecule cancer-targeted molecular radiotherapeutic, by predicting efficacy and enabling calculation of efficacious doses of HOT for Phase 2 trials, the company said.